<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
		>
<channel>
	<title>Comments on: Would Comparative Effectiveness Reduce Patients’ Options?</title>
	<atom:link href="http://blog.pharmtech.com/2009/06/22/would-comparative-effectiveness-reduce-patients%e2%80%99-options/feed/" rel="self" type="application/rss+xml" />
	<link>http://blog.pharmtech.com/2009/06/22/would-comparative-effectiveness-reduce-patients%e2%80%99-options/</link>
	<description>The blog of Pharmaceutical Technology magazine</description>
	<lastBuildDate>Tue, 07 Feb 2012 17:25:13 -0500</lastBuildDate>
	<generator>http://wordpress.org/?v=2.8.4</generator>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
		<item>
		<title>By: Erik Greb</title>
		<link>http://blog.pharmtech.com/2009/06/22/would-comparative-effectiveness-reduce-patients%e2%80%99-options/comment-page-1/#comment-15301</link>
		<dc:creator>Erik Greb</dc:creator>
		<pubDate>Fri, 26 Jun 2009 17:16:48 +0000</pubDate>
		<guid isPermaLink="false">http://blog.pharmtech.com/?p=1451#comment-15301</guid>
		<description>Hi, Jack. Thanks for your comment. The idea that comparative-effectiveness research (CER) will lead to medical decisions that ignore differences between individual patients is commonly held. The government seems to have a procedure in place to take such concerns into consideration.

The Federal Coordinating Council for Comparative Effectiveness Research was created to help federal agencies coordinate CER. The Council held three listening sessions to obtain public comment before it makes its report and recommendations to Congress on June 30, 2009.

In the course of the listening sessions, attendees made the following comments:

“CER must account for the individual nature of patient characteristics, including their specific preferences and personal values.”

“CER must develop the ability to account for both the important individual differences in physiology and risk faced by patients making decisions about their care and for individual patient preferences.”

See http://www.hhs.gov/recovery/programs/cer/summary_june10.html
 for other comments.

I believe that these comments will be included in the Council’s report and will guide the way CER is conducted. 

Erik</description>
		<content:encoded><![CDATA[<p>Hi, Jack. Thanks for your comment. The idea that comparative-effectiveness research (CER) will lead to medical decisions that ignore differences between individual patients is commonly held. The government seems to have a procedure in place to take such concerns into consideration.</p>
<p>The Federal Coordinating Council for Comparative Effectiveness Research was created to help federal agencies coordinate CER. The Council held three listening sessions to obtain public comment before it makes its report and recommendations to Congress on June 30, 2009.</p>
<p>In the course of the listening sessions, attendees made the following comments:</p>
<p>“CER must account for the individual nature of patient characteristics, including their specific preferences and personal values.”</p>
<p>“CER must develop the ability to account for both the important individual differences in physiology and risk faced by patients making decisions about their care and for individual patient preferences.”</p>
<p>See <a href="http://www.hhs.gov/recovery/programs/cer/summary_june10.html" rel="nofollow">http://www.hhs.gov/recovery/programs/cer/summary_june10.html</a><br />
 for other comments.</p>
<p>I believe that these comments will be included in the Council’s report and will guide the way CER is conducted. </p>
<p>Erik</p>
]]></content:encoded>
	</item>
	<item>
		<title>By: Jack Coupal</title>
		<link>http://blog.pharmtech.com/2009/06/22/would-comparative-effectiveness-reduce-patients%e2%80%99-options/comment-page-1/#comment-15233</link>
		<dc:creator>Jack Coupal</dc:creator>
		<pubDate>Fri, 26 Jun 2009 03:43:52 +0000</pubDate>
		<guid isPermaLink="false">http://blog.pharmtech.com/?p=1451#comment-15233</guid>
		<description>Comparative-effectiveness criteria will lead to a one-size-fits-all approach in any government scheme. 

You have symptoms A, B, and Q, plus signs B, N, and Z. In addition, you are Z years old: therefore you will receive Treatment L.

Individualizing treatment will be considered &quot;too expensive&quot; as a cost-cutting tool. The American public will never accept such mechanical  health care.</description>
		<content:encoded><![CDATA[<p>Comparative-effectiveness criteria will lead to a one-size-fits-all approach in any government scheme. </p>
<p>You have symptoms A, B, and Q, plus signs B, N, and Z. In addition, you are Z years old: therefore you will receive Treatment L.</p>
<p>Individualizing treatment will be considered &#8220;too expensive&#8221; as a cost-cutting tool. The American public will never accept such mechanical  health care.</p>
]]></content:encoded>
	</item>
</channel>
</rss>

